Cetera Investment Advisers
RNTX

Cetera Investment Advisers’s Rein Therapeutics RNTX Stock Holding History

Cetera Investment Advisers’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,364
Closed -$14.3K – 4999
2025
Q4 		$14.3K Hold
12,364
– – ﹤0.01% 4596
2025
Q3 		$14.2K Sell
12,364
-1,282
-9% -$1.63K ﹤0.01% 4509
2025
Q2 		$19.1K Buy
+13,646
New +$24.6K ﹤0.01% 4027
2022
Q4 		– Sell
-1,312
Closed -$5K – 2176
2022
Q3 		$5K Buy
1,312
+437
+50% +$1.85K ﹤0.01% 1675
2022
Q2 		$5K Hold
875
– – ﹤0.01% 1808
2022
Q1 		$9K Sell
875
-42
-5% -$380 ﹤0.01% 1854
2021
Q4 		$10K Buy
+917
New +$14.2K ﹤0.01% 1846

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Cetera Investment Advisers's RNTX Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Rein Therapeutics (RNTX) in Q1 2026, closing a stake of 12,364 shares — an estimated $14.3K sold.

Cetera Investment Advisers first reported a position in RNTX in Q4 2021 and held it in 7 quarters. The position peaked at $19.1K in Q2 2025. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Rein Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 12,364 Rein Therapeutics shares in Q1 2026, an estimated $14.3K.
  • Cetera Investment Advisers first reported a position in Rein Therapeutics in Q4 2021 and held it in 7 quarters.
  • Cetera Investment Advisers's Rein Therapeutics position peaked at $19.1K in Q2 2025.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.